Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder R (2021)


Publication Type: Journal article

Publication year: 2021

Journal

DOI: 10.1002/ehf2.13622

Abstract

Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this study was to analyse the effect of empagliflozin on vascular function in patients with HF.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C.,... Schmieder, R. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.13622

MLA:

Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC Heart Failure (2021).

BibTeX: Download